June 21, 2018

Polatuzumab Vedotin Plus BR Demonstrates Higher PET-CR in DLBCL

The addition of polatuzumab vedotin to bendamustine and rituximab (Rituxan; BR) induced a higher rate of complete responses by PET scan (PET-CR) compared with BR alone in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), according to phase II findings presented by Laurie H. Sehn, MD, during the 2018 European Hematology Association Congress. {read more here}